Skip to main content
. 2023 Jun 8;10(4):2524–2533. doi: 10.1002/ehf2.14426

Figure 4.

Figure 4

Cost‐effectiveness acceptability curve showing the maximum willingness to pay and the corresponding probability of cost‐effectiveness for dapagliflozin group and standard group. WTP, willingness‐to‐pay.